Company Filing History:
Years Active: 2002-2004
Title: Jan Domin: Innovator in Class II PI3 Kinase Research
Introduction
Jan Domin is a prominent inventor based in London, GB. He has made significant contributions to the field of biochemistry, particularly in the study of class II PI3 kinases. With a total of 2 patents, his work has implications for cancer research and therapeutic development.
Latest Patents
Jan Domin's latest patents include a screening method for ligands with class II PI3 kinase modulating activity. This invention introduces a novel human class II PI3 kinase, termed PI3K-C2α, which possesses unique biochemical properties. These properties distinguish it from previously known PI3 kinases, including resistance to the inhibitors Wortmannin and LY294000, the absence of a p85 binding site, a divergent amino terminus, and the lack of a polyproline motif typical of known type II PI3 kinases. Another significant patent relates to the sequence of the isolated nucleic acid molecule and the encoded amino acid sequence of this novel human class II PI3-kinase.
Career Highlights
Jan Domin is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in the field. His work has garnered attention for its innovative approach to understanding PI3 kinases and their role in cancer biology.
Collaborations
Jan has collaborated with notable colleagues, including Michael Derek Waterfield, enhancing the impact of his research through shared expertise and insights.
Conclusion
Jan Domin's contributions to the field of biochemistry, particularly through his patents on class II PI3 kinases, highlight his role as an influential inventor in cancer research. His innovative work continues to pave the way for future advancements in therapeutic strategies.